New hope for hard-to-treat liver cancer spread: personalized combo therapy shows promise
NCT ID NCT06199232
First seen Jan 30, 2026 · Last updated May 23, 2026 · Updated 20 times
Summary
This study tests a new treatment for people with advanced colorectal cancer that has spread to the liver and no longer responds to standard therapies. The approach combines a liver-directed chemotherapy infusion (HAIC), an immunotherapy drug (tislelizumab), and targeted drugs chosen based on a blood test (ctDNA) that looks at the tumor's genetic makeup. The goal is to control the disease and improve survival, not to cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER METASTASIS COLON CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Peking Univerisity Cancer Hospital
Beijing, Beijing Municipality, 100142, China
Conditions
Explore the condition pages connected to this study.